These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30963442)

  • 1. Increased MDR1 Transporter Expression in Human Brain Endothelial Cells Through Enhanced Histone Acetylation and Activation of Aryl Hydrocarbon Receptor Signaling.
    You D; Wen X; Gorczyca L; Morris A; Richardson JR; Aleksunes LM
    Mol Neurobiol; 2019 Oct; 56(10):6986-7002. PubMed ID: 30963442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain region-specific regulation of histone acetylation and efflux transporters in mice.
    You D; Shin HM; Mosaad F; Richardson JR; Aleksunes LM
    J Biochem Mol Toxicol; 2019 Jun; 33(6):e22318. PubMed ID: 30897286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic Regulation of Multidrug Resistance Protein 1 and Breast Cancer Resistance Protein Transporters by Histone Deacetylase Inhibition.
    You D; Richardson JR; Aleksunes LM
    Drug Metab Dispos; 2020 Jun; 48(6):459-480. PubMed ID: 32193359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling.
    Kekatpure VD; Dannenberg AJ; Subbaramaiah K
    J Biol Chem; 2009 Mar; 284(12):7436-45. PubMed ID: 19158084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aza-PBHA, a potent histone deacetylase inhibitor, inhibits human gastric-cancer cell migration via PKCα-mediated AHR-HDAC interactions.
    Tsai CH; Li CH; Liao PL; Chang YW; Cheng YW; Kang JJ
    Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118564. PubMed ID: 31672612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aryl hydrocarbon receptor (AHR) regulation of L-Type Amino Acid Transporter 1 (LAT-1) expression in MCF-7 and MDA-MB-231 breast cancer cells.
    Tomblin JK; Arthur S; Primerano DA; Chaudhry AR; Fan J; Denvir J; Salisbury TB
    Biochem Pharmacol; 2016 Apr; 106():94-103. PubMed ID: 26944194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated level of lysine 9-acetylated histone H3 at the MDR1 promoter in multidrug-resistant cells.
    Toth M; Boros IM; Balint E
    Cancer Sci; 2012 Apr; 103(4):659-69. PubMed ID: 22320423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aryl hydrocarbon receptor regulates CYP1B1 but not ABCB1 and ABCG2 in hCMEC/D3 human cerebral microvascular endothelial cells after TCDD exposure.
    Jacob A; Potin S; Chapy H; Crete D; Glacial F; Ganeshamoorthy K; Couraud PO; Scherrmann JM; Declèves X
    Brain Res; 2015 Jul; 1613():27-36. PubMed ID: 25858487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic evidence of an Ac/Dc axis by VPA and SAHA.
    Lunke S; Maxwell S; Khurana I; K N H; Okabe J; Al-Hasani K; El-Osta A
    Clin Epigenetics; 2021 Mar; 13(1):58. PubMed ID: 33743782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-Catenin Is Required for Endothelial Cyp1b1 Regulation Influencing Metabolic Barrier Function.
    Ziegler N; Awwad K; Fisslthaler B; Reis M; Devraj K; Corada M; Minardi SP; Dejana E; Plate KH; Fleming I; Liebner S
    J Neurosci; 2016 Aug; 36(34):8921-35. PubMed ID: 27559173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells.
    To KK; Polgar O; Huff LM; Morisaki K; Bates SE
    Mol Cancer Res; 2008 Jan; 6(1):151-64. PubMed ID: 18234970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproate increases dopamine transporter expression through histone acetylation and enhanced promoter binding of Nurr1.
    Green AL; Zhan L; Eid A; Zarbl H; Guo GL; Richardson JR
    Neuropharmacology; 2017 Oct; 125():189-196. PubMed ID: 28743636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of indoleamine 2,3-dioxygenase 1 expression in neurons of the central nervous system through inhibition of histone deacetylases blocks the progression of experimental autoimmune encephalomyelitis.
    Kim CE; Lee SM; Yoon EH; Won HJ; Jung YJ; Jegal Y; Kim DH; Kwon B; Seo SK
    Int Immunopharmacol; 2024 Jun; 134():112246. PubMed ID: 38759372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
    Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma.
    Wang LT; Chiou SS; Chai CY; Hsi E; Wang SN; Huang SK; Hsu SH
    Oncotarget; 2017 Jan; 8(5):7489-7501. PubMed ID: 27283490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
    You BR; Han BR; Park WH
    Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular histone deacetylation by pharmacological HDAC inhibition.
    Rafehi H; Balcerczyk A; Lunke S; Kaspi A; Ziemann M; Kn H; Okabe J; Khurana I; Ooi J; Khan AW; Du XJ; Chang L; Haviv I; Keating ST; Karagiannis TC; El-Osta A
    Genome Res; 2014 Aug; 24(8):1271-84. PubMed ID: 24732587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of histone deacetylase inhibitors on the Ah receptor gene promoter.
    Garrison PM; Rogers JM; Brackney WR; Denison MS
    Arch Biochem Biophys; 2000 Feb; 374(2):161-71. PubMed ID: 10666294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine.
    David GL; Yegnasubramanian S; Kumar A; Marchi VL; De Marzo AM; Lin X; Nelson WG
    Cancer Biol Ther; 2004 Jun; 3(6):540-8. PubMed ID: 15034303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy.
    Valdez BC; Li Y; Murray D; Brammer JE; Liu Y; Hosing C; Nieto Y; Champlin RE; Andersson BS
    Oncotarget; 2016 Sep; 7(39):63829-63838. PubMed ID: 27564097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.